Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BPMCNASDAQ:KYMRNASDAQ:LEGNNASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBPMCBlueprint Medicines$128.12-0.1%$103.81$73.04▼$128.34$8.27B0.841.24 million shs3.48 million shsKYMRKymera Therapeutics$46.44+0.2%$34.61$19.45▼$53.27$3.02B2.07615,919 shs517,555 shsLEGNLegend Biotech$34.89+0.5%$32.24$27.34▼$60.87$6.41B0.131.34 million shs884,227 shsSRPTSarepta Therapeutics$20.77-3.7%$43.71$18.30▼$173.25$2.04B0.612.06 million shs7.51 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBPMCBlueprint Medicines0.00%-0.07%+24.39%+44.41%+20.06%KYMRKymera Therapeutics0.00%-1.80%+47.71%+42.72%+48.85%LEGNLegend Biotech0.00%-7.97%+16.03%-5.58%-13.81%SRPTSarepta Therapeutics0.00%-44.33%-48.06%-71.97%-82.33%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBPMCBlueprint Medicines1.0092 of 5 stars2.12.00.00.01.90.80.6KYMRKymera Therapeutics3.4473 of 5 stars4.53.00.00.03.61.70.0LEGNLegend Biotech2.5592 of 5 stars3.51.00.00.04.21.70.6SRPTSarepta Therapeutics4.5592 of 5 stars4.32.00.04.21.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBPMCBlueprint Medicines 2.27Hold$128.06-0.05% DownsideKYMRKymera Therapeutics 3.00Buy$59.8228.82% UpsideLEGNLegend Biotech 2.91Moderate Buy$76.20118.40% UpsideSRPTSarepta Therapeutics 2.54Moderate Buy$70.76240.68% UpsideCurrent Analyst Ratings BreakdownLatest KYMR, LEGN, BPMC, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025BPMCBlueprint MedicinesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.006/17/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.006/17/2025SRPTSarepta TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoveragePeer Perform6/16/2025SRPTSarepta TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$125.00 ➝ $54.006/16/2025SRPTSarepta TherapeuticsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$113.00 ➝ $40.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBPMCBlueprint Medicines$508.82M16.26N/AN/A$4.70 per share27.26KYMRKymera Therapeutics$47.07M64.25N/AN/A$12.90 per share3.60LEGNLegend Biotech$627.24M10.22N/AN/A$5.70 per share6.12SRPTSarepta Therapeutics$1.90B1.07$2.43 per share8.53$15.99 per share1.30Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBPMCBlueprint Medicines-$67.09M-$2.47N/A197.11N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)KYMRKymera Therapeutics-$223.86M-$3.10N/AN/AN/A-409.07%-30.11%-25.65%8/6/2025 (Estimated)LEGNLegend Biotech-$177.03M-$0.59N/AN/AN/A-29.95%-21.19%-13.47%8/8/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.90N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest KYMR, LEGN, BPMC, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025LEGNLegend Biotech-$0.40-$0.07+$0.33-$0.27$190.83 million$195.05 million5/9/2025Q1 2025KYMRKymera Therapeutics-$0.92-$0.82+$0.10-$0.82$11.38 million$22.10 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 million5/1/2025Q1 2025BPMCBlueprint Medicines-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBPMCBlueprint MedicinesN/AN/AN/AN/AN/AKYMRKymera TherapeuticsN/AN/AN/AN/AN/ALEGNLegend BiotechN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBPMCBlueprint Medicines1.012.802.75KYMRKymera TherapeuticsN/A8.498.49LEGNLegend Biotech0.305.205.07SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBPMCBlueprint MedicinesN/AKYMRKymera TherapeuticsN/ALEGNLegend Biotech70.89%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipBPMCBlueprint Medicines4.21%KYMRKymera Therapeutics16.01%LEGNLegend Biotech0.02%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBPMCBlueprint Medicines64064.58 million61.86 millionOptionableKYMRKymera Therapeutics17065.12 million54.69 millionOptionableLEGNLegend Biotech2,609183.76 million183.73 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableKYMR, LEGN, BPMC, and SRPT HeadlinesRecent News About These CompaniesTD Cowen Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to HoldJune 20 at 2:29 AM | americanbankingnews.comWhat’s next for Sarepta Therapeutics with gene therapy under fire?June 19 at 11:10 AM | statnews.comDeutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceJune 19 at 4:03 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at The Goldman Sachs GroupJune 19 at 4:03 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $75.00 at Wells Fargo & CompanyJune 19 at 1:43 AM | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)June 19 at 1:11 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTJune 18 at 12:42 PM | globenewswire.comSarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)June 18 at 11:39 AM | marketbeat.comMizuho Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $40.00June 18 at 11:23 AM | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 3% After Analyst DowngradeJune 18 at 10:39 AM | marketbeat.comSarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall StreetJune 18 at 10:17 AM | tipranks.comSRPT NOTICE: Did Sarepta Therapeutics, Inc. Mislead Investors about the Safety of Elevidys? Contact BFA Law if You Lost Money (NASDAQ:SRPT)June 18 at 8:38 AM | globenewswire.comSarepta Therapeutics (NASDAQ:SRPT) Downgraded to "Hold" Rating by TD CowenJune 18 at 8:05 AM | marketbeat.comRobert W. Baird Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceJune 18 at 2:58 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Stock Rating Lowered by BMO Capital MarketsJune 18 at 2:25 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Downgraded by HC Wainwright to SellJune 18 at 2:25 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given "Neutral" Rating at Cantor FitzgeraldJune 18 at 1:51 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Given Equal Weight Rating at Morgan StanleyJune 18 at 1:51 AM | americanbankingnews.comJefferies Financial Group Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $54.00June 18 at 1:51 AM | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Reaches New 12-Month Low After Analyst DowngradeJune 18 at 1:12 AM | americanbankingnews.comSarepta Therapeutics: Overcoming Challenges and Capturing Growth Opportunities Amid Elevidys SetbackJune 17 at 7:24 PM | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAnalysts Can't Get Enough of These Little-Known Biopharma StocksBy Nathan Reiff | June 12, 2025View Analysts Can't Get Enough of These Little-Known Biopharma StocksKYMR, LEGN, BPMC, and SRPT Company DescriptionsBlueprint Medicines NASDAQ:BPMC$128.12 -0.11 (-0.09%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$128.14 +0.02 (+0.02%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Kymera Therapeutics NASDAQ:KYMR$46.44 +0.09 (+0.19%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$46.36 -0.08 (-0.17%) As of 06/18/2025 04:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.Legend Biotech NASDAQ:LEGN$34.89 +0.19 (+0.55%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$34.96 +0.06 (+0.19%) As of 06/18/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Sarepta Therapeutics NASDAQ:SRPT$20.77 -0.79 (-3.66%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$20.68 -0.09 (-0.41%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
